Chiral Materials for the Recognition and Inhibition of Amyloid‐β Aggregation

ABSTRACT Abnormal aggregation of amyloid‐β (Aβ) peptides is a central pathological event in Alzheimer's disease (AD), closely associated with neurotoxicity and disease progression. The development of molecules or materials with high selectivity and affinity toward Aβ aggregates constitutes an essential component for the early diagnosis and intervention of AD. Aβ peptides, composed of homochiral amino acids, undergo intermolecular β‐sheet assembly to form supramolecular chiral aggregates, providing a structural basis for chirality‐sensitive recognition. Therefore, chiral materials have attracted significant attention in Aβ aggregates recognition and regulation. Previous reviews have examined different types of chiral materials for the inhibition of Aβ aggregation, including chiral small molecules, amino acids, peptides, and various chiral interfaces or nanomaterials. The present review organizes reported chiral materials according to three intervention strategies for modulating Aβ aggregation: conformation‐locking, self‐assembly‐induced remodeling, and multifunctional intervention. We summarize representative materials in each category, along with the corresponding design principles and modulation performance toward Aβ aggregation. Current challenges and potential directions for the development of chiral therapeutics for AD are also discussed.